N. Nassr

发表

Steady-State Pharmacokinetics of Roflumilast and Roflumilast N-Oxide in Patients with Mild and Moderate Liver Cirrhosis

R. Hermann, É. Péterfai, C. Mey, 2007, Clinical pharmacokinetics.

The Targeted Oral, Once‐Daily Phosphodiesterase 4 Inhibitor Roflumilast and the Leukotriene Receptor Antagonist Montelukast Do Not Exhibit Significant Pharmacokinetic Interactions

C. Gleiter, R. Hermann, G. Lahu, 2009, Journal of clinical pharmacology.

Absence of Pharmacokinetic Interaction Between Roflumilast and Digoxin in Healthy Adults

G. Eckermann, G. Lahu, T. Bethke, 2012, Journal of clinical pharmacology.

Supra-therapeutic doses of roflumilast have no effect on cardiac repolarization in healthy subjects

G. Lahu, D. Bredenbröker, N. Nassr, 2011, Expert opinion on drug safety.

Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.

Ronan Roussel, Timothy S. Bailey, T. Bailey, 2017, Diabetes & metabolism.

Pharmacokinetic evaluation of roflumilast

G. Lahu, N. Nassr, A. Hünnemeyer, 2011, Expert opinion on drug metabolism & toxicology.

No Dose Adjustment on Coadministration of the PDE4 Inhibitor Roflumilast With a Weak CYP3A, CYP1A2, and CYP2C19 Inhibitor: An Investigation Using Cimetidine

A. Walz, C. Gleiter, K. Mörike, 2011, Journal of clinical pharmacology.

Effect of Steady‐State Enoxacin on Single‐Dose Pharmacokinetics of Roflumilast and Roflumilast N‐Oxide

M. Elmlinger, P. Ruth, M. Hinder, 2011, Journal of clinical pharmacology.

Magnesium Hydroxide/Aluminium Hydroxide‐Containing Antacid Does Not Affect the Pharmacokinetics of the Targeted Phosphodiesterase 4 Inhibitor Roflumilast

R. Hermann, O. Richter, G. Lahu, 2007, Journal of clinical pharmacology.

Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects

R. Hermann, K. Erb, B. Schug, 2007 .

Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects.

K. Duffy, R. Hermann, O. von Richter, 2009, British journal of clinical pharmacology.

Dipyrone and diclofenac do not influence creatinine-clearance, inulin-clearance or PAH-clearance in healthy male volunteers.

K. Farker, B. Rosenkranz, A. Hoffmann, 1995, International journal of clinical pharmacology and therapeutics.

Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype

Li Jin, Alexander A. Vinks, Magnus Ingelman-Sundberg, 2006, Pharmacogenetics and genomics.

No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study

C. D. De Mey, G. Lahu, N. Nassr, 2011, BMC clinical pharmacology.

Measurements of urinary prostaglandins in young ovulatory women during the menstrual cycle and in postmenopausal women.

R. Vollandt, H. Seyberth, K. Farker, 1997, Prostaglandins.

Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity

M. Ingelman-Sundberg, R. Hermann, O. Richter, 2006, Clinical pharmacology and therapeutics.

No Dose Adjustment on Coadministration of the PDE4 Inhibitor Roflumilast With a Weak CYP3A, CYP1A2, and CYP2C19 Inhibitor: An Investigation Using Cimetidine

A. Walz, C. Gleiter, K. Mörike, 2011, Journal of clinical pharmacology.